Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd-Rüdiger Burmester

Showing results (151-160 of 171) with videos related to

Pageof 18
Sort By:
Annals of the Rheumatic Diseases|March 15, 2022
Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseasesAmanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Fredrik N Albach, et al.
Arthritis Research & Therapy|October 13, 2016
Sequential high-content profiling of the IgG-autoantibody repertoire reveals novel antigens in rheumatoid arthritisStefan Vordenbäumen, Angelika Lueking, Petra Budde, et al.
Cellular & Molecular Immunology|November 11, 2014
Effects of 60-day bed rest with and without exercise on cellular and humoral immunological parametersPaula Hoff, Daniel L Belavý, Dörte Huscher, et al.
Nature Communications|February 2, 2026
Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trialLennard Ostendorf, Jan Zernicke, Jens Klotsche, et al.
Arthritis and Rheumatism|September 2, 2006
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksStanley B Cohen, Paul Emery, Maria W Greenwald, et al.
The Lancet. Rheumatology|January 17, 2024
Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trialJens Y Humrich, Caroline von Spee-Mayer, Elise Siegert, et al.
Bone|April 11, 2013
Preoperative irradiation for the prevention of heterotopic ossification induces local inflammation in humansPaula Hoff, Anastasia Rakow, Timo Gaber, et al.
RMD Open|November 2, 2022
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional studyFabian Proft, Julia Schally, Henning Christian Brandt, et al.
Therapeutic Advances in Musculoskeletal Disease|April 4, 2022
Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional studyFabian Proft, Julia Schally, Henning Christian Brandt, et al.
Annals of the Rheumatic Diseases|February 25, 2015
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusTobias Alexander, Ramona Sarfert, Jens Klotsche, et al.
Pageof 18

Showing results (151-160 of 171) with videos related to

Sort By:
Pageof 18
Annals of the Rheumatic Diseases|March 15, 2022
Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseasesAmanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Fredrik N Albach, et al.
Arthritis Research & Therapy|October 13, 2016
Sequential high-content profiling of the IgG-autoantibody repertoire reveals novel antigens in rheumatoid arthritisStefan Vordenbäumen, Angelika Lueking, Petra Budde, et al.
Cellular & Molecular Immunology|November 11, 2014
Effects of 60-day bed rest with and without exercise on cellular and humoral immunological parametersPaula Hoff, Daniel L Belavý, Dörte Huscher, et al.
Nature Communications|February 2, 2026
Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trialLennard Ostendorf, Jan Zernicke, Jens Klotsche, et al.
Arthritis and Rheumatism|September 2, 2006
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksStanley B Cohen, Paul Emery, Maria W Greenwald, et al.
The Lancet. Rheumatology|January 17, 2024
Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trialJens Y Humrich, Caroline von Spee-Mayer, Elise Siegert, et al.
Bone|April 11, 2013
Preoperative irradiation for the prevention of heterotopic ossification induces local inflammation in humansPaula Hoff, Anastasia Rakow, Timo Gaber, et al.
RMD Open|November 2, 2022
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional studyFabian Proft, Julia Schally, Henning Christian Brandt, et al.
Therapeutic Advances in Musculoskeletal Disease|April 4, 2022
Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional studyFabian Proft, Julia Schally, Henning Christian Brandt, et al.
Annals of the Rheumatic Diseases|February 25, 2015
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusTobias Alexander, Ramona Sarfert, Jens Klotsche, et al.
Pageof 18